Brigitte Dreno, MD; Alain Huart, MD; Eric Billaud, MD; Pierre Litoux, MD; Wandrille Y. Godefroy, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: Recent in-vitro studies (1) have suggested that interferons may inhibit endothelial cell proliferation, and in-vivo regression has also been reported during long-term therapy with α-interferon in Kaposi sarcoma (2). Interferon appears to act not only by affecting endothelial cells directly but also by enhancing angiogenesis inhibitors or modulating the signals inducing angiogenesis (1).
Contrary to these results, we have noted the development of cutaneous vascular lesions with punctate telangiectasias (3 to 8 mm in diameter) in 18 patients of 44 patients treated with interferon-α2a (18 X 106 U daily for 2 months, then 12 X 106 U
Dreno B, Huart A, Billaud E, Litoux P, Godefroy WY. Alpha-Interferon Therapy and Cutaneous Vascular Lesions. Ann Intern Med. ;111:95–96. doi: 10.7326/0003-4819-111-1-95_2
Download citation file:
Published: Ann Intern Med. 1989;111(1):95-96.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use